News

News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.

Featured news

Donanemab update: new Alzheimer’s disease treatment approved by the FDA

On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease.  Donanemab is the…

Published date:

Celebrating 40 years of ADI

This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.

Published date:

#WhatsYourPlan

To date, only 37 of 194 countries that signed up to implement the WHO Global action plan on dementia have created and funded national dementia plans. Our new campaign aims to galvanise and encourage more governments to develop national dementia plans following their 2017 commitment.

Published date:

Regional member meetings for Latin America and Asia Pacific

ADI hosted its first virtual regional meeting for ADI members in Latin America, since the COVID-19 pandemic began, on 12 November. The second virtual regional meeting Asia Pacific took place a week later on 12 November. During the Latin America meeting, 18 participants from 13 countries were in attendance. The 2-hour meeting…

Published date: